The COVAX global vaccine-sharing program has delivered 1 billion COVID-19 vaccine doses, one of the organizations which manages it said on January 15.
If you are not happy with the results below please do another search
50 search results for:
U.S. households can order four free at-home COVID-19 tests from the website COVIDTests.gov starting on Jan. 19 with shipping expected within seven to 12 days of ordering, the White House said on Jan. 14.
The U.S. Food and Drug Administration approved drugs from AbbVie Inc. and Pfizer Inc. for treating the skin disease eczema, the companies said on Jan. 14.
After a five-day quarantine, about a third of people infected with SARS-CoV-2 might still be infectious, according to new data. In other news, according to research published in the Journal of Primary Care & Community Health, e-cigarette users infected with the coronavirus may be more likely than infected non-vapers to experience COVID-19 symptoms
Gilead Sciences Inc. on Jan. 14 notified the U.S. health regulator of the company’s decision to voluntarily withdraw the use of the drug Zydelig for two types of cancer – follicular lymphoma and small lymphocytic leukemia.
Johnson & Johnson on January 14 said the company agreed to pay $44 million to resolve claims that it fueled the opioid epidemic in New Mexico, a state which originally opted against participating in a nationwide settlement resolving thousands of similar cases.
A U.S. judge on January 14 barred Martin Shkreli from the pharmaceutical industry for life and ordered him to pay $64.6 million after he famously raised the price of the drug Daraprim and fought to block generic competitors.
On January 3, 2022, a marvel of intelligence and ingenuity departed from the life science community in the form of Beatrice Mintz, who passed three weeks before her 101st birthday. Born in the Big Apple on January 24, 1921, Dr. Mintz would grow up to become one of the pioneering minds of modern embryology, whose trailblazing research would pave the way for current explorations of genetics.
Emergent BioSolutions came into 2022 after a challenging year that saw the company lose a lucrative contract with the U.S. government following a production mishap that ruined millions of doses of Johnson & Johnson’s COVID-19 vaccine.
After a strong 2021 that included the acquisition of GW Pharmaceuticals, the approval of the acute lymphoblastic leukemia drug Rylaze and the achievement of $3 billion in annual revenue, Jazz Pharmaceuticals set the company’s sights on nearly doubling that return by 2025.